Intuitive, Fosun Pharma launch $100M JV for robotic-assisted lung cancer Dx

The da Vinci surgical system--Courtesy of Intuitive Surgical

Robotic surgery leader Intuitive Surgical is teaming up with its Chinese distribution partner Fosun Pharma on a joint venture to develop and market robotic-assisted, catheter-based medical devices.

The companies will pitch in up to $100 million for the JV, which will be registered in Shanghai, according to a statement. It will initially focus on devices to help in the early diagnosis of and cost-effective treatment of lung cancer, the companies said. The JV will distribute the devices in China, while Intuitive will handle distribution elsewhere.

Intuitive Surgical is the leader in minimally invasive, robotic-assisted surgery and has worked with Fosun subsidiary Chindex Medical since 2011, when the latter started distributing Intuitive’s da Vinci surgical systems in China.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Meanwhile, Fosun Pharma covers several segments of the healthcare industry, including pharma manufacturing, diagnostics, devices and pharma distribution and retail. Its R&D efforts span multiple therapeutic areas, such as the cardiovascular and central nervous systems, metabolism and the anti-infection and antitumor disciplines. The JV will bolster Fosun’s medical device segment, said Chen Qiyu, Fosun Pharma chairman, in the statement.

“We are excited to deepen our partnership with Fosun Pharma focused on delivering innovative healthcare solutions in China and around the world,” said Intuitive CEO Gary Guthart, in the statement. “We are proud to make this important long-term commitment to China.”

Suggested Articles

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.

A new company focusing on sperm rather than egg biology debuted with goals of increasing fertility rates and reducing pregnancy complications.

Verily has obtained a second agency green light for measuring irregular heartbeats using its prescription smartwatch.